New Cycle Capital

Care Daily is an Internet of Things (IoT) software company that specializes in developing cloud-based solutions for smart home and smart building applications. Founded in 2009 and headquartered in Palo Alto, California, Care Daily offers a comprehensive suite of products designed to facilitate the connection, engagement, and management of IoT devices. Its offerings include the People Power Energy Service Platform, which transforms real-time data from energy-consuming devices into insightful reports, and various mobile applications that enhance user interaction with connected devices. Additionally, Care Daily provides tools such as open-source APIs for manufacturers to integrate their products and a command center for device management. The company's solutions cater to both residential and commercial users, enabling them to monitor and control their energy consumption effectively. Care Daily also focuses on remote senior care and family connectivity through its Presence Family Care Pack, alongside advanced services such as HVAC fault detection powered by artificial intelligence.

GoalSpring Financial, Inc. offers DebtGoal, an online application that enables users to organize, optimize, and pay their debt. It operates DebtGoals.Com, an online debt management service that takes into account customer's debt, such as credit cards, student loans, car loans, and mortgages, as well as enables them to organize, optimize, and pay-down their debt. GoalSpring Financial, Inc. was founded in 2008 and is based in San Francisco, California.

SavvyMoney, Inc. is a fintech company based in Pleasanton, California, founded in 2008. It offers an online platform that allows individuals to check their credit scores and compare financial products, including credit cards, personal loans, and car loans, aimed at helping users save money. The company provides integrated credit score and personal finance solutions to over 125 credit unions and banks, featuring free credit score access, reports, and daily monitoring. SavvyMoney's pre-qualification offer engine presents tailored financial offers based on users' credit profiles. The platform is designed to educate and empower users to improve their financial health while enabling financial institutions to focus on assisting consumers rather than merely identifying leads.

Renew Financial specializes in providing innovative financing solutions aimed at supporting contractors in the renewable energy and energy efficiency sectors. Founded in 2008 by Cisco DeVries, the company focuses on promoting energy independence and transitioning to a clean energy economy. Its primary offerings include the Property Assessed Clean Energy (PACE) financing model and the Warehouse for Energy Efficiency Loans, which facilitate access to financing for residential energy efficiency projects by attracting institutional investors. Renew Financial's platform provides both secured and unsecured financing options to homeowners, contractors, and local governments, enabling them to undertake energy, safety, and water efficiency improvements. This approach not only helps property owners reduce energy consumption but also aids local governments in creating jobs and fostering sustainable development.

REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an office in San Francisco, California. Founded in 2006, it specializes in developing immune-regulatory therapeutics aimed at treating life-threatening diseases and disorders. The company utilizes its proprietary reVax technology, which induces regulatory T cells to promote immune tolerance against specific disease-causing antigens. REGiMMUNE's product pipeline includes RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, as well as RGI-3001, a preclinical candidate for type 1 diabetes. Its portfolio also addresses a range of conditions, including allergies, autoimmune diseases, and transplantation disorders, with a focus on reducing the side effects commonly associated with conventional immunosuppressants. The company's research efforts are directed towards developing innovative solutions for various immune system disorders, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.

Opower, Inc. is a leading provider of cloud-based software solutions for the utility industry, focused on enhancing customer engagement and promoting energy efficiency. The company collaborates with over 85 utility partners, serving more than 18 million consumers across seven countries. Its software analyzes energy usage data and delivers personalized insights to motivate consumers to reduce their energy consumption. Opower's offerings include home energy reports, smart meter-enabled communications, and a marketplace suite for product recommendations. Additionally, the company provides demand response solutions, such as alerts and feedback reports to encourage reduced energy use during peak times. Opower also enhances digital engagement through customer-facing web applications and tools aimed at improving customer satisfaction. Founded in 2007 and headquartered in Arlington, Virginia, Opower operates as a subsidiary of Oracle Corporation.

REGiMMUNE Corporation is a biotechnology company based in Tokyo, Japan, with an office in San Francisco, California. Founded in 2006, it specializes in developing immune-regulatory therapeutics aimed at treating life-threatening diseases and disorders. The company utilizes its proprietary reVax technology, which induces regulatory T cells to promote immune tolerance against specific disease-causing antigens. REGiMMUNE's product pipeline includes RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, as well as RGI-3001, a preclinical candidate for type 1 diabetes. Its portfolio also addresses a range of conditions, including allergies, autoimmune diseases, and transplantation disorders, with a focus on reducing the side effects commonly associated with conventional immunosuppressants. The company's research efforts are directed towards developing innovative solutions for various immune system disorders, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus.